{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-088029","form_type":"8-K","ticker":"APGE","cik":"0001974640","company_name":"Apogee Therapeutics, Inc.","filed_at":"2024-08-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:15.304277+00:00","generated_at":"2026-05-31T10:10:57.659877+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Apogee reports Q2 net loss $33.8M; cash $789.6M; APG777 Phase 2 dosing started","bullets":["Q2 2024 net loss $33.8M ($18.9M in Q2 2023); R&D expenses $33.2M, up from $13.9M.","Cash $789.6M as of June 30, 2024; runway into Q1 2028.","First patient dosed in APG777 Phase 2 trial; 16-week proof-of-concept data expected 2H2025.","APG808 interim Phase 1 data Q4 2024; APG990 Phase 1 trial accelerated to Q3 2024.","Added APG333 (anti-TSLP) to pipeline; entering clinic in 2025; combinations planned."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-088029","json":"https://secwatch.observer/filing/0001104659-24-088029.json","markdown":"https://secwatch.observer/filing/0001104659-24-088029.md","text":"https://secwatch.observer/filing/0001104659-24-088029.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1974640/000110465924088029/0001104659-24-088029-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1974640/000110465924088029/tm2421302d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T10:10:57.659877+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}